Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001070873 | SCV001236151 | uncertain significance | not provided | 2023-02-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GALNT12 protein function. ClinVar contains an entry for this variant (Variation ID: 863818). This variant has not been reported in the literature in individuals affected with GALNT12-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 76 of the GALNT12 protein (p.Gly76Ser). |
Ambry Genetics | RCV004030764 | SCV002736619 | uncertain significance | not specified | 2023-04-05 | criteria provided, single submitter | clinical testing | The p.G76S variant (also known as c.226G>A), located in coding exon 1 of the GALNT12 gene, results from a G to A substitution at nucleotide position 226. The glycine at codon 76 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. The evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear. |
Baylor Genetics | RCV004570306 | SCV005058842 | uncertain significance | Colorectal cancer, susceptibility to, 1 | 2023-12-14 | criteria provided, single submitter | clinical testing |